Duchesnay Inc. and Tzamal Medical Group Ltd sign an agreement for the drug Diclectin® for the management of nausea and vomiting of pregnancy
BLAINVILLE, QC and TEL AVIV, Israel, Jan. 16, 2013 /CNW Telbec/ - Duchesnay Inc. and Tzamal Medical Group Ltd today announced that they have signed an agreement whereby Tzamal Medical Group has been granted exclusive rights to distribute and sell throughout the Israeli market the prescription medicine Diclectin® (doxylamine 10 mg/pyridoxine 10 mg delayed-release tablet) indicated for the management of nausea and vomiting of pregnancy (NVP).
"We are very pleased to partner with Tzamal Medical Group, a successful and trusted industry leader in the field of medical and pharmaceutical specialty products", said Éric Gervais, Executive Vice-President of Duchesnay Inc. "This strategic collaboration represents an important milestone in our endeavor to help pregnant women suffering from nausea and vomiting of pregnancy (NVP). We are excited to enable expectant mothers within the Israeli market to have access to a proven safe and effective pharmacological treatment for NVP."
"Diclectin ®, as a delayed release combination proved its impeccable efficacy and safety in North America / Canada for years and as such recommended as first choice by both the Society Obstetricians and Gynaecologists of Canada (SOGC) and the American College of Obstetricians and Gynaecologists (ACOG)" - said E. Steinberg , CEO of Tzamal BioPharma Ltd, the pharmaceutical arm of Tzamal Medical Ltd - "and we are confident that the available solid clinical and safety data of the drug will allow the Israeli MOH to approve it as the first drug to address specifically for NVP, a very important unmet need of the pregnant women up to now".
Diclectin®, a delayed-release combination of doxylamine and vitamin B6, is the only antinauseant and antiemetic drug labelled and approved for use in pregnancy in Canada. Its long and outstanding track record of safety and efficacy has made Diclectin® the medicine of choice in Canada for over 30 years. In the Drugs in Pregnancy and Lactation Reference Guide, Briggs has assigned Diclectin® the highest safety rating: "Compatible" or "Category A".
ABOUT NAUSEA AND VOMITING OF PREGNANCY (NVP)
Nausea and vomiting of pregnancy (NVP), commonly called morning sickness, affects between 70 to 85 percent of pregnant women. If left untreated, symptoms can sometimes progress to a potentially more serious condition called hyperemesis gravidarum (HG), which may require hospitalization. NVP can have a dramatic impact on the emotional and physical well-being of the expectant woman and her family. NVP has also been shown to impose an economic burden on healthcare costs and lost productivity.
Duchesnay Inc. is a Canadian specialty pharmaceutical company dedicated to improve the health and quality of life of pregnant women by working at advancing maternal-fetal medicine to reduce the risk of birth defects and by developing safe and effective pharmacological solutions for use during pregnancy and breastfeeding. For more information, visit http://www.duchesnay.com/en/.
ABOUT TZAMAL MEDICAL GROUP
Tzamal Medical Group is a leading provider of pharmaceuticals, medical devices and equipment for the global healthcare industry. Tzamal Medical Group promotes leading global healthcare and creates leverage both in the Israeli and global medical markets. For more information, visit www.tzamal-medical.co.il
SOURCE Duchesnay inc.
Image with caption: "Diclectin - Nausea and Vomiting of Pregnancy (CNW Group/Duchesnay inc.)". Image available at: http://photos.newswire.ca/images/download/20130116_C5985_PHOTO_EN_22616.jpg